Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NCOA3
REST API REST API
Homo sapiens
NCOA3 is differentially expressed in 352 experiments: 148 organism parts: placenta, tonsil, ... (146 more);, 200 disease states: normal, glioblastoma, ... (198 more);, 122 cell types 471 cell lines 56 compound treatments and 86 other conditions.
Synonyms TRAM-1, CAGH16, KAT13B, p/CIP, bHLHe42, RAC3, TNRC16, AIB1, SRC-3, ACTR, SRC3
Orthologs NCOA3 (Gallus gallus)   Ncoa3 (Mus musculus)   ncoa3 (Danio rerio)   NCOA3 (Bos taurus)   Ncoa3 (Rattus norvegicus)   ncoa3 (Xenopus laevis)   NCOA3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term ligand-dependent nuclear receptor binding, protein binding, histone acetyltransferase activity, regulation of transcription, DNA-dependent, cytoplasm, developmental growth, protein N-terminus binding, Golgi apparatus, signal transducer activity, multicellular organism growth, positive regulation of transcription from RNA polymerase II promoter, transcription coactivator activity, nucleus, histone acetylation, ligand-dependent nuclear receptor transcription coactivator activity, receptor activity, chromatin binding, nucleoplasm, signal transduction, positive regulation of transcription, DNA-dependent, transferase activity, transferring acyl groups, androgen receptor binding, androgen receptor signaling pathway, positive regulation of estrogen receptor signaling pathway, positive regulation of steroid hormone receptor signaling pathway, nuclear hormone receptor binding, estrogen receptor binding, thyroid hormone receptor binding, mammary gland branching involved in thelarche, cellular lipid metabolic process, vagina development, positive regulation of sequence-specific DNA binding transcription factor activity
InterPro Term PAS, PAS_fold, Nuc_rcpt_coact_Ncoa-typ, Nuclear_rcpt_coactivator, DUF1518, SRC-1, HLH_DNA-bd
UniProt Accession Q569F6, Q9Y6Q9, Q0IIN7, C9JCR8, B4DYS9, B4DYT5
Search EB-eye ENSG00000124151
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-7224, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (47 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081, E-GEOD-5823
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
HL-60
3
E-GEOD-5258, E-GEOD-24147, E-MTAB-37
SNU1
2
E-MTAB-37, E-GEOD-15460
A549
2
E-GEOD-3202, E-GEOD-6013
BT-474
2
E-GEOD-5823, E-GEOD-3529
465 more value(s).


Cell type

studied in E-GEOD-492, E-MEXP-1121, E-GEOD-3920, E-GEOD-20677, E-TABM-34, ... (55 experiments)

Factor Value U/D Experiments
CD8+ T cell
5
E-AFMX-5, E-TABM-145, E-GEOD-6740, E-MTAB-25, E-GEOD-19069 ... (5 experiments)
embryonic stem cell
2
E-GEOD-2248, E-MEXP-930
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18265
CD34+
2
E-AFMX-5, E-TABM-145
1
2
E-TABM-145, E-TABM-130
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
116 more value(s).


Disease state

studied in E-GEOD-1615, E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, ... (72 experiments)

Factor Value U/D Experiments
septic shock
2
E-GEOD-8121, E-GEOD-9692
chronic myelogenous leukemia
2
E-MTAB-37, E-GEOD-5550
leiomyosarcoma
2
E-MEXP-1922, E-GEOD-6481
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
melanoma
2
E-MTAB-37, E-MTAB-62
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
194 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-5824, E-GEOD-3720, E-TABM-868, E-MEXP-1958, ... (35 experiments)

Factor Value U/D Experiments
none
3
8
E-TABM-782, E-MEXP-1958, E-GEOD-20719, E-GEOD-5824, E-MEXP-1601, ... (11 experiments)
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
MIG control
1
E-GEOD-15811
filtered air
1
E-TABM-127
interleukin-4 (Homo sapiens) + anti-CD40
1
E-GEOD-7307
phorbol 12-myristate 13-acetate + ionomycin
1
E-GEOD-3720
50 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
1
E-GEOD-19519
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-860, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-MEXP-480, E-GEOD-7788, E-GEOD-22148, E-MEXP-2280, ... (9 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-MEXP-1996, E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-TABM-601, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-21612, E-MEXP-2657, E-GEOD-20540, E-TABM-440, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-MEXP-1648, ... (41 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, ... (7 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-TABM-321

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-19069, E-GEOD-7307, E-GEOD-1295

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-11886, E-GEOD-23984, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-19136, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-6532, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.576 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM